Market LIVE
Published markets; coverage varies by country
Product profile · United States

ORSERDU

 ·  Patent Litigation & Settlement History ↓

IngredientELACESTRANT HYDROCHLORIDE
Application typeNDA
Application217639
Product002
Dosage formTABLET
RouteORAL
StrengthEQ 345MG BASE
Approval date2023-01-27
Marketing statusPrescription
Status event—
ApplicantSTEMLINE THERAP
Product source

Current GenericRadar decision

Year2037
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeDS_EQUIVALENT_PATENT
Anchor date2037-02-28
Patent anchor2037-02-28
Exclusivity anchor2028-01-27
Protection date2038-01-05
First Final ANDA—
Status event—

POST_ANCHOR_RIGHTS_EXIST; US:NDA:217639:002; exact Final ANDA not verified; not proof of generic absence

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
76121142026-08-18DS/DP/U U-3523YNTRUE_DS
| B1C03P7 issued-claim review2026-10-15: TRUE_DS
———
76121142026-08-18ORANGE_BOOK U-3523YNTRUE_DS
English description not available.
———
100710662034-10-10U U-3524NNU
| B1C03P7 issued-claim review2026-10-15: U
———
100710662034-10-10ORANGE_BOOK U-3524NNU
English description not available.
———
117795522034-10-10U U-3524NNU
| B1C03P7 issued-claim review2026-10-15: U
———
117795522034-10-10ORANGE_BOOK U-3524NNU
English description not available.
———
104207342036-10-03U U-3524NNU
| B1C03P7 issued-claim review2026-10-15: U
———
104207342036-10-03ORANGE_BOOK U-3524NNU
English description not available.
———
118194802037-02-28U U-3523NYU
| B1C03P7 issued-claim review2026-10-15: U
———
118194802037-02-28ORANGE_BOOK U-3523NYU
English description not available.
———
103850082038-01-05DS/DP —NNDP
| B1C03P7 issued-claim review2026-10-15: DP
———
103850082038-01-05ORANGE_BOOK —NNDP
English description not available.
———
107453432038-01-05U U-3523NNU
| B1C03P7 issued-claim review2026-10-15: U
———
107453432038-01-05ORANGE_BOOK U-3523NNU
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2023-01-272028-01-27English description not available.YY2028-01-27—Source
NCE2023-01-272028-01-27English description not available.YY2028-01-27
NCE
Full coverage date: 2028-01-27
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (9)
TypeDateRoleBasisSource
PATENT2026-08-18HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2034-10-10HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2034-10-10HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2036-10-03HISTORICAL_CONTEXTEnglish description not available.Source
PATENT2037-02-28CANONICAL_ANCHOREnglish description not available.Source
PATENT2038-01-05FTO_TAILEnglish description not available.Source
PATENT2038-01-05FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—REGULATORY_SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_STATUS2037-02-28CANONICAL_DECISIONPOST_ANCHOR_RIGHTS_EXIST; US:NDA:217639:002; exact Final ANDA not verified; not proof of generic absenceSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.